Bob Casey Linked to Chinese Fentanyl Company in Senate Race

In a contentious Senate race in Pennsylvania, incumbent Democrat Bob Casey faces scrutiny over his investments in a Chinese fentanyl manufacturer, Humanwell, which he criticized in a recent campaign ad targeting Republican challenger Dave McCormick. Casey's campaign accused McCormick of profiting from the fentanyl crisis through his previous role at Bridgewater Associates, which invested $1.7 million in Humanwell. However, it has been revealed that Casey himself holds a minimal stake in the company through a college savings plan managed by Fidelity. McCormick responded to Casey's accusations by highlighting the senator's perceived hypocrisy, stating that Casey has had nearly two decades to address the fentanyl crisis but has failed to secure the border effectively. He emphasized that Casey's investments contradict his claims of moral superiority in the fight against fentanyl, which has contributed to over 5,000 overdose deaths in Pennsylvania last year alone. The debate over fentanyl has intensified as both candidates seek to position themselves as the better choice for voters concerned about the opioid epidemic. Casey's campaign maintains that he never directly chose to invest in Humanwell, while McCormick's team argues that the senator's investments reflect a broader issue of career politicians failing to take responsibility. As the 2024 election approaches, Pennsylvania is poised to play a crucial role in determining control of the Senate and the presidential race, with the fentanyl crisis emerging as a key issue for voters.